Skip to content

Investigating the effect of exercise and creatine supplement in Chronic Fatigue Syndrome

"Examining the effect of eight-week aerobic and strength exercise program with Creatine supplement on performance and fatigue in patients with Chronic Fatigue Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20111025007903N14
Enrollment
36
Registered
2024-10-04
Start date
2024-05-20
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Fatigue Syndrome. Postviral fatigue syndrome, Myalgic encephalomyelitis

Interventions

Intervention 1: Intervention group: creatine supplement (produced by Karen company) is consumed for one month in the form of 25 grams in 5 divided doses in the first 5 days and then in the amount of 5

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65 years Meet US National Academy Of Medicine criteria (NAM), (have cognitive and/or orthostatic symptoms along with three of the following: A) substantial decrease or impairment in ability to participate in pre-illness levels of occupational, educational, social, or personal activities that has persisted for 6 months or more and is accompanied by profound fatigue, has a new onset (not lifelong), is not the result of ongoing excessive exertion, and is not significantly relieved by rest ???B) Post-exertional malaise (PEM) C) Sleep that is not restorative. Must have moderate to severe fatigue.

Exclusion criteria

Exclusion criteria: Currently have respiratory failure due to uncontrolled cardiopulmonary disease or COVID-19. Existence of acute infectious symptoms such as fever and vital sign abnormalities. Existence of severe musculoskeletal symptoms or other diseases that interfere with exercise. Existence history of severe allergies, neurological, rheumatological, or psychological disorders that significantly impact fatigue. Existence history of kidney disease, proteinuria, or abnormal kidney function tests such as elevated BUN and creatinine.

Design outcomes

Primary

MeasureTime frame
Fatigue severity in Chalder's questionnaire. Timepoint: Before starting the intervention, ending the intervention. Method of measurement: Chalder's questionnaire.

Secondary

MeasureTime frame
Function, Quality of Life. Timepoint: Before starting the intervention, ending the intervention. Method of measurement: GPAQ questionnaire, SF-36 questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Alizadeh

Tehran University of Medical Sciences

z_alizadeh@tums.ac.ir+98 21 6119 2282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026